Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Christian-Albrechts-Universität Zu Kiel currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This case is reviewed by 1 distinct examiner, HUTTER, GILLIAN A, in 1 distinct art unit. As the busiest examiner, HUTTER, GILLIAN A handles the 1 pending action that makes up the university's current workload. This focused activity involves only one specific set of examiner guidelines and art unit standards, which can streamline the prosecution process.
Because the university is managing only 1 pending office action, it can focus its resources on the specific technical challenges presented by the 1 distinct art unit. The outcome of this biotechnology matter depends entirely on the interpretation of HUTTER, GILLIAN A, who is the 1 distinct examiner assigned to the case. Practitioners should prioritize a thorough review of this examiner's previous actions to ensure that the response to the 1 pending office action is tailored to her specific procedural and technical preferences.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUTTER, GILLIAN A | 1 | 54.5% | +46.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18010045 | MARC1 INHIBITORS FOR TREATMENT OF LIPID METABOLISM DISORDERS | HUTTER, GILLIAN A | 50d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18010045 | MARC1 INHIBITORS FOR TREATMENT OF LIPID METABOLISM DISORDERS | HUTTER, GILLIAN A | 50d overdue |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18010045 | MARC1 INHIBITORS FOR TREATMENT OF LIPID METABOLISM DISORDERS | HUTTER, GILLIAN A | 1625 | §102§103§112 | Final Rejection | 50d overdue | Pending | Feb 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialChristian-Albrechts-Universität Zu Kiel has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Gillian A Hutter has the most, with 1 of Christian-Albrechts-Universität Zu Kiel's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
